Key Highlights
- 10-state outbreak of infant botulism linked to ByHeart baby formula.
- Thirteen babies hospitalized; no deaths reported.
- FDA recall includes two lots with December 1 “use by” dates.
- New York City-based ByHeart says taking proactive step for safety.
Infant Botulism Outbreak Sparks ByHeart Formula Recall
The U.S. Food and Drug Administration (FDA) has ordered the recall of certain lots of organic baby formula produced by ByHeart after a 10-state outbreak of infant botulism was linked to the product, federal health officials said.
Since August, 13 infants have been hospitalized in connection with this outbreak. While no deaths have been reported so far, the disease can be fatal and poses serious health risks for young children.
Timeline and Impact of the Recall
The FDA has issued a recall notice for two specific lots of ByHeart Whole Nutrition Infant Formula with December 1 “use by” dates. The lot numbers are 206VABP/251261P2 and 206VABP/251131P2. Parents and caregivers who have the product are advised to record identifying information from the bottom of the packaging and discard it immediately.
The recall affects a small portion of the baby formula market, as ByHeart makes up less than 1% of all infant formulas sold in the United States. However, the company is taking proactive steps due to concerns raised by government agencies.
Understanding Infant Botulism and Treatment
Infant botulism occurs when a baby ingests Clostridium botulinum spores from contaminated food or environment. These spores can grow in the infant’s gut, producing toxins that lead to paralysis. Symptoms include constipation, poor feeding, and difficulty swallowing, which can progress to more severe conditions if left untreated.
The FDA recommends parents and caregivers who have recently fed ByHeart formula to their infants keep a close eye on them as botulism symptoms may take weeks to develop.
ByHeart’s Response and Future Steps
New York City-based ByHeart stated that it was informed by the FDA of 83 reported cases across the nation since August. While government tests have not yet identified botulism in its product, the company is removing potentially impacted products from store shelves as a precaution.
A spokesperson for ByHeart said, “ByHeart is taking the proactive step to remove any potential risk from the market and ensure the highest level of safety for infants.” The company added that government tests are ongoing, and it will continue to cooperate with regulatory agencies to determine the source of contamination.
Health experts recommend that parents who have concerns about their baby’s health seek medical advice promptly. Treatment options include an FDA-approved “orphan drug” called BabyBIG, which consists of antibodies to fight botulinum neurotoxins.
The outbreak and subsequent recall highlight the ongoing challenges in ensuring infant formula safety and the need for continuous monitoring by public health agencies.
